ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Oxandrolone with 10mg DHEA at the end: blood tests and my experience
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Rock H. Johnson" data-source="post: 174156" data-attributes="member: 39049"><p>P-12 A FISHER, M ABBATICOLA Stratogen Health and Brown University, 400 Reservoir Avenue, Providence, RI 02907 USA EFFECTS OF OXANDROLONE AND L-GLUTAMINE ON BODY WEIGHT, BODY CELL MASS, AND BODY FAT IN PATIENTS WITH HIV INFECTION-PRELIMINARY ANALYSIS Background: Oxandrolone is an orally bioavailable anabolic steroid indicated to offset muscle catabolism. Glutamine is the most abundant amino acid in the body, is stored in skeletal muscle, and is released in response to physiological stress. Depletion of glutamine is a causative factor in AIDS-related wasting. Body cell mass (BCM) represents total functioning cells; normally 60% BCM is muscle. Body Fat (BF) consists of metabolically inactive cells. Loss of BCM is the key factor in AIDS wasting morbidity and mortality. BCM and BF are accurately measured by bioelectric impedance analysis (BIA). Objectives: To measure the response of body weight (BW), BCM and BF by BIA in patients with HIV infection and weight loss to oxandrolone given with glutamine (O/G) in a phase IV clinical trial. Methods: Patients with AIDS and weight loss were offered open label oxandrolone 20 mg daily with glutamine 20 g daily. BIA was performed at baseline and periodically during the time on study. The patients were stable on antiretroviral therapy regimens and free of acute infections. Results: 16 male patients entered the study. The treatment time at analysis was 33+12 (+lSD) days. Al1 patients gained BW (mean: 2.92 2.4 kg) and BCM (mean 1.2-cO.7 kg). Both changes are highly significant (p=O.OOOI). A small insignificant increase in BF was observed (mean: 0.7-C 1.7 kg). The treatment regimen was well tolerated. No side-effects were observed. Patients continuing treatment will be periodically w-evaluated over the course of one year. Conclusions: Treatment with O/G resulted in significant weight gain, increased BCM, and did not promote excess BF gain in this group of patients with HIV infection and weight loss at baseline.</p></blockquote><p></p>
[QUOTE="Rock H. Johnson, post: 174156, member: 39049"] P-12 A FISHER, M ABBATICOLA Stratogen Health and Brown University, 400 Reservoir Avenue, Providence, RI 02907 USA EFFECTS OF OXANDROLONE AND L-GLUTAMINE ON BODY WEIGHT, BODY CELL MASS, AND BODY FAT IN PATIENTS WITH HIV INFECTION-PRELIMINARY ANALYSIS Background: Oxandrolone is an orally bioavailable anabolic steroid indicated to offset muscle catabolism. Glutamine is the most abundant amino acid in the body, is stored in skeletal muscle, and is released in response to physiological stress. Depletion of glutamine is a causative factor in AIDS-related wasting. Body cell mass (BCM) represents total functioning cells; normally 60% BCM is muscle. Body Fat (BF) consists of metabolically inactive cells. Loss of BCM is the key factor in AIDS wasting morbidity and mortality. BCM and BF are accurately measured by bioelectric impedance analysis (BIA). Objectives: To measure the response of body weight (BW), BCM and BF by BIA in patients with HIV infection and weight loss to oxandrolone given with glutamine (O/G) in a phase IV clinical trial. Methods: Patients with AIDS and weight loss were offered open label oxandrolone 20 mg daily with glutamine 20 g daily. BIA was performed at baseline and periodically during the time on study. The patients were stable on antiretroviral therapy regimens and free of acute infections. Results: 16 male patients entered the study. The treatment time at analysis was 33+12 (+lSD) days. Al1 patients gained BW (mean: 2.92 2.4 kg) and BCM (mean 1.2-cO.7 kg). Both changes are highly significant (p=O.OOOI). A small insignificant increase in BF was observed (mean: 0.7-C 1.7 kg). The treatment regimen was well tolerated. No side-effects were observed. Patients continuing treatment will be periodically w-evaluated over the course of one year. Conclusions: Treatment with O/G resulted in significant weight gain, increased BCM, and did not promote excess BF gain in this group of patients with HIV infection and weight loss at baseline. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Oxandrolone with 10mg DHEA at the end: blood tests and my experience
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top